Hua Medicine (HK:2552) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hua Medicine has reported substantial growth with its HuaTangNing product’s sales volume increasing to 846,000 packs in the first half of 2024, a significant rise from 212,000 packs in the same period last year, resulting in a 46% revenue increase to RMB102.7 million. Despite a price reduction from entering China’s National Reimbursement Drug List, the company’s gross profit margin stands at 46.5%. Additionally, Hua Medicine is expanding dorzagliatin manufacturing capacity and progressing with post-marketing clinical studies, indicating a positive long-term outlook for the drug.
For further insights into HK:2552 stock, check out TipRanks’ Stock Analysis page.